Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04381884

Recruitment Status : Completed

First Posted : May 11, 2020

Last Update Posted : October 5, 2020

Sponsor:

Collaborators:

Universidad Nacional de Salta

Centro de Investigación Veterinaria Tandil CIVETAN

Hospital de Pediatría Prof Dr. Juan P. Garrahan

Universidad Nacional de Quilmes

Information provided by (Responsible Party):

Laboratorio Elea Phoenix S.A.

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	September 29, 2020
Actual Study Completion Date :	September 29, 2020

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Krolewiecki A, Lifschitz A, Moragas M, Travacio M, Valentini R, Alonso DF, Solari R, Tinelli MA, Cimino RO, Álvarez L, Fleitas PE, Ceballos L, Golemba M, Fernández F, Fernández de Oliveira D, Astudillo G, Baeck I, Farina J, Cardama GA, Mangano A, Spitzer E, Gold S, Lanusse C. Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial. EClinicalMedicine. 2021 Jun 18;37:100959. doi: 10.1016/j.eclinm.2021.100959. eCollection 2021 Jul. Erratum in: EClinicalMedicine. 2021 Sep;39:101119.

To Top